Opportunities in the Wake of COVID-19
• 6 min read
Get the latest in Research & Insights
Sign up to receive a weekly email summary of new articles posted to AMG Research & Insights.
"*" indicates required fields
Click the “Play” Arrow on the image above to view our 4/30 webinar recording.
WEBINAR SUMMARY: OPPORTUNITIES IN THE WAKE OF COVID-19
Nuggets of Opportunity
AMG offers tips on where to prospect for gems as U.S. economy starts reopening.
AMG National Trust sees several investment opportunities emerging in the coming months as America gets back to business following the COVID-19 economic lockdown.
Savvy investors should explore:
- Small and midcap stocks.
- Foreign stocks.
- Value stocks.
Additionally, two market sectors in particular are offering relatively large discounts: energy and financials.
Those areas are more likely to provide better returns as the United States and the world slowly reopen parts of the global economy over the next two months. But keep in mind that while stock markets have bounced back nicely since the March 23 crash, the coming weeks are likely to be volatile.
“Markets are still in the bottoming process … that likely means we might test the bottom, but we probably won’t go below it,” said Josh Stevens, AMG’s Senior Vice President-Investment Group. His comments came during AMG’s April 30 Insights briefing on the pandemic’s economic impact. Click here to watch the video.
Bad economic news will roll in over the coming months, keeping markets jittery and unlikely to mount a sustained climb. Just this week, new government estimates showed real GDP in the first quarter slid an annualized 4.8% after four quarters of solid growth in 2019.
Dr. Michael Bergmann, AMG’s Senior Executive VP and Economist, estimates that dip will be well over 25% annualized in the second quarter — the worst in U.S. history.
“The next 60 days will test our courage as investors,” said Earl Wright, AMG’s Chairman.
Buoying markets is encouraging news in the global crusade against COVID-19, which, in less than five months, has infected at least 3.2 million people and killed 230,000 — over 60,000 in the United States alone. Here’s the latest:
- U.S. infection rates, although bumpy, seem to have plateaued. Over 180 treatments for the disease are in the works, and early testing for one, Remdesivir, shows it may cut patient recovery times by 30%. Nearly 100 vaccines are in development. The University of Oxford is leading the way, and clinical trials on its vaccine could be completed by August. The research is so promising that manufacturing and distribution systems are being set up so production could start in September if all goes well.
- The Federal Reserve continues to flood the economy with about $7 trillion in liquidity through a number of programs, primarily executed through banks and credit markets, and the federal government is adding another $2.2 trillion, primarily in the form of small-business loans, relief checks for individuals and enhanced unemployment benefits.
- A growing number of states are cautiously lifting economic restrictions. If states continue to meet the gating criteria, America should remain on a path to reopening 60% of its economy by July 1, more than 80% by Oct. 1 and 100% by Dec. 31, according to AMG’s research. This is barring a material, expansive second wave of infections.
All of this news matches up with AMG’s base-case scenario for economic recovery, which estimates normal growth patterns won’t return until 2022. In 2021, AMG sees quarterly growth showing some startling double-digit numbers as the economy revs back to life, returns to nearly full production, and recovers from the COVID-19 downturn.
“The bottom line is that the Fed is willing to do whatever it takes,” Dr. Bergmann said, “while Congress and the administration are not far behind in using monetary and fiscal tools; first, to act as a lifeline that keeps financial markets functioning, and households and businesses solvent in the near term; and then second, to provide economic stimulus as a recovery in production takes hold.”
That bodes well for investors.
AMG research has identified three areas of public market opportunity coming out of this crisis.
- Small- and mid-cap stocks are likely to outperform large-cap stocks during the recovery. They are cheap relative to large caps and historically better reflect economic growth. Large-cap stock overall valuations and earnings have been somewhat misleading because just five corporate behemoths—Apple, Google, Amazon, Facebook, and Microsoft—account for 21% of the S&P 500, while 350 stocks make up the bottom 21%. Small-cap profit growth, although more volatile than large-cap, often recovers fastest from a recession and is well sustained through economic recovery periods.
- Foreign stocks appear poised to do better than domestic stocks. Foreign stocks have underperformed since 2008-’09 Great Recession, in large part because they were beset by several financial upheavals that the United States escaped: the 2011-2012 European debt crisis, China’s 2014-2016 economic restructuring and commodities bust, and the United Kingdom’s 2016 Brexit vote. Foreign stocks—both developing markets and European markets – have stronger profit recoveries following most recessions.
- Value stocks appear primed to earn more than growth stocks. Growth stocks’ valuations are at the highest point since the 2001 tech bubble relative to value equities. Historically, value stocks have significantly outpaced broader growth-stock indices during economic recoveries.
In addition, equities in several market sectors are deeply discounted right now: primarily energy and financial, but also industrial and materials. Talk to an AMG advisor for more information about specific investment opportunities.
If the United States and the world can avoid a big second wave of COVID-19 infections causing a retightening of economic restrictions, the outlook for a 2021 economic recovery looks good.
“At the moment, most of the financial markets are focused on finding the bottom in corporate profits and economic activity, and then looking at the path to recovery,” Stevens said.
Low interest rates, easy-money policies, and federal relief efforts probably will continue for at least the next 12 to 24 months, which should make it a good time for investment.
But all the government’s deficit spending to combat the pandemic raises the specter of a ballooning national debt and its inflationary pull.
FISCAL YEAR DEFICITS AND PUBLIC DEBT
The Congressional Budget Office estimates that U.S. debt will reach the equivalent of 101% of the GDP by the end of fiscal year 2020 and 108% by the end of fiscal year 2021.
“We don’t have anything to worry about in the short-run,” said Dr. Bergmann, “but it is obviously a potential long-term issue.”
Corporations also could be competing for capital against a vastly expanded U.S. bond market, which finances the federal debt. That could cause higher interest rates, less capital investment in free enterprise, and less growth in the economy, Wright said.
“Interest rates are really low right now,” said Wright, “but if the cost of the federal debt was approximately 5%, our current interest payments would go from 5% to 20% of the federal budget.”
The mountainous debt, coupled with rising interest rates, could eventually force America to increase taxes, reduce government programs, or eliminate needed new ones.
Inflation also eventually could become a problem, Wright said, but not for the next two to three years as the Federal Reserve floods the economy with cash to ensure the recovery continues.
“Regardless,” he said, “it would suggest you want to invest accordingly: in equities and real assets to protect against inflation.”
This information is for general information use only. It is not tailored to any specific situation, is not intended to be investment, tax, financial, legal, or other advice and should not be relied on as such. AMG’s opinions are subject to change without notice, and this report may not be updated to reflect changes in opinion. Forecasts, estimates, and certain other information contained herein are based on proprietary research and should not be considered investment advice or a recommendation to buy, sell or hold any particular security, strategy, or investment product.